B
Bull
Bull · 25%CLSD
$2.29
Scenario price
$0.410
-0.111 (-26.96%)At close
Loading chart…
- High
- 0.585
- Open
- 0.570
- VWAP
- 0.46
- Vol
- 2.77M
- Mkt Cap
- 95.66M
- Low
- 0.370
- Amount
- 1.26M
- EV/EBITDA, TTM
- 0.00
Clearside Biomedical, Inc. is a biopharmaceutical company focused on the delivery of therapies to the back of the eye through the suprachoroidal space (SCS). The Company's SCS injection platform, utilizing its patented SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. The Company is developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector. The Company's lead program, CLS-AX (axitinib injectable suspension), for the treatment of neovascular age-related macular degeneration (wet AMD). It developed and gained approval for its product, XIPERE (triamcinolone acetonide injectable suspension) for suprachoroidal use, which is available in the United States through a commercial partner.
Analyst Ratings (6)
Buy
6 Buy
0 Hold
0 Sell
Current: 0.41
Low
—
Average
—
High
—
Chardan
Neutral
—
2025-07-18
Chardan
2025-07-18
Price Target
—
Neutral
H.C. Wainwright
Neutral
—
2025-07-18
H.C. Wainwright
2025-07-18
Price Target
—
Neutral
JonesResearch
Hold
—
2025-07-17
JonesResearch
2025-07-17
Price Target
—
Hold
Needham
Hold
$3
2025-07-17
Needham
2025-07-17
Price Target
$3
Hold
Stifel
Hold
$2
2025-07-17
Stifel
2025-07-17
Price Target
$2
Hold
Valuation Metrics
The current forward P/E ratio for Clearside Biomedical Inc (CLSD) is -2.05, compared to its 5-year average forward P/E of -7.34.
Alphio AI Price Scenarios for CLSD
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Events Timeline
News
4.511-24BenzingaNasdaq Rises by 350 Points; Enlivex Therapeutics Stock Jumps Significantly
9.011-24NewsfilterClearside Biomedical Files for Chapter 11 Bankruptcy, Seeks Asset Auction
- 9.011-24TipRanks
What’s Causing the Decline in Clearside Biomedical Stock (CLSD) Today?
9.011-24NASDAQ.COMClearside Biomedical Submits Voluntary Chapter 11 Bankruptcy Petition
9.011-24NASDAQ.COMClearside Biomedical Initiates Chapter 11 Bankruptcy Proceedings
CLSD FAQ — answered by Alphio AI
Clearside Biomedical, Inc. is a biopharmaceutical company focused on the delivery of therapies to the back of the eye through the suprachoroidal space (SCS). The Company's SCS injection platform, utilizing its patented SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. The Company is developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector. The Company's lead program, CLS-AX (axitinib injectable suspension), for the treatment of neovascular age-related macular degeneration (wet AMD). It developed and gained approval for its product, XIPERE (triamcinolone acetonide injectable suspension) for suprachoroidal use, which is available in the United States through a commercial partner. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
6 analysts cover CLSD: 6 rate it Buy, 0 Hold and 0 Sell.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.